Galena Biopharma (GALE -4.3%) gives a pipeline update at ASCO, saying that NeuVax continues to...

|About: Galena Biopharma, Inc. (GALE)|By:, SA News Editor

Galena Biopharma (GALE -4.3%) gives a pipeline update at ASCO, saying that NeuVax continues to demonstrate "durable response rates", and that a companion diagnostic for HER2 screening in women with breast cancer "increases accuracy." It also reported positive results from Phase 1/2a studies of its folate binding protein, HLA-A2, a restricted peptide immunotherapy for treating ovarian and endometrial cancer.